Enfortumab Vedotin Plus Pembrolizumab with Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
Patients with MIBC will receive 3 cycles (C1-C3) of induction enfortumab vedotin plus
pembrolizumab followed by restaging including MRI of the bladder, urine cytology, and
cystoscopy with TURBT of any visible tumor and/or resection site plus random biopsies
using a r...
Age: 18 years - 66+
Gender: All
Ritlecitinib (PF-06651600) in Participants With Chronic Spontaneous Urticaria
The purpose of this research study is to see if a drug called ritlecitinib is safe and
effective for treating chronic spontaneous urticaria (CSU). CSU is hives and itching
lasting over six weeks. Ritlecitinib is approved by the Food and Drug Administration
(FDA) to t...
Age: 18 - 65 years
Gender: All
Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
The goal of this observational study is to understand how genomic and epigenetic factors
contribute to resistance against chemo-immunotherapy in adults diagnosed with
extensive-stage small cell lung cancer (ES-SCLC) or metastatic large cell neuroendocrine
carcinoma (...
Age: 18 - 85 years
Gender: All
WATER IV Prostate Cancer
This is a multicenter, prospective, randomized clinical trial that aims to assess the
safety and efficacy of Aquablation Therapy in men with low-risk to intermediate to
high-risk localized prostate cancer who are candidates for, or have opted for,
prostatectomy. Part...
Age: 45 years - 66+
Gender: Male
A Study of Pembrolizumab (MK-3475) With or Without V940 in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
The goal of this study is to learn if people who receive V940 and pembrolizumab after
surgery are cancer-free longer than people who receive placebo and pembrolizumab.
Researchers want to know if giving V940 and pembrolizumab after surgery can help prevent
the cancer...
Age: 18 years - 66+
Gender: All
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
This is a study for people with advanced cancer for whom previous treatment was not
successful or no treatment exists. Adults aged 18 and over with advanced cancer with HER2
alterations can join the study. The purpose of this study is to find out whether a
medicine c...
Age: 18 years - 66+
Gender: All
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
This is a phase 2 open-label two cohort study of durvalumab plus monalizumab in patients
with BCG-unresponsive or exposed CIS NMIBC. Arm A will enroll 43 participants who have
cancer in situ (CIS) with or without high grade papillary urothelial cancer. Arm B will
enr...
Age: 18 years - 66+
Gender: All
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to assess the safety and efficacy of divarasib compared to
locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS
G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC).
Age: 18 years - 66+
Gender: All
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe,
tolerable and effective in participants with advanced, or metastatic solid tumors
including urothelial cancer. The study is conducted in two parts - phase Ia
(dose-escalation, dose-o...
Age: 18 years - 66+
Gender: All
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
This phase I trial tests the safety, side effects, best dose, and effectiveness of
emavusertib (CA-4948) in combination with pembrolizumab in treating patients with
urothelial cancer that has spread from where it first started to other places in the body
(metastatic)...
Age: 18 years - 66+
Gender: All
Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)
The purpose of this study is to measure the effect and safety of treatment with
tuvusertib combined with either niraparib or lartesertib in participants with epithelial
ovarian cancer. The participants will previously have progressed while treated with a
poly ADP rib...
Age: 18 years - 66+
Gender: Female
Assessment of Supportive Care and Educational Needs to Guide Quality Care Improvements for Patients With Locally Advanced and Metastatic Bladder Cancer
The overall goal of this study is to facilitate care improvements for bladder cancer patients with locally advanced or metastatic disease by designing and evaluating a patient need assessment screening tool to be used, in the future, as standard screening measure. Adult...
Age: 18 - 89 years
Gender: All
Enhancing Access to Supportive Services for Women of Color with Metastatic Breast Cancer
Black and Latina women experience disparities in supportive and palliative care access
and outcomes. The goal of the proposed pilot study is to evaluate the feasibility and
acceptability of a community navigator delivered supportive care intervention for
historically...
Age: 18 years - 66+
Gender: Female
Tailoring Therapy in Post-surgical Patients With Low-risk Endometrial Cancer
This phase II trial tests how well tailoring therapy in post-surgery works in patients
with low-risk endometrial cancer. The usual approach for patients with low-risk
endometrial cancer is treatment with surgery. In this study, tissue that is removed as
part of the s...
Age: 18 years - 66+
Gender: Female
A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
Genes contain genetic code which tell the body which proteins to make. Some types of
cancer are caused by changes, or mutations, in a gene called KRAS. Researchers are
looking for ways to stop the actions of abnormal proteins made from the mutated KRAS
gene. The so-c...
Age: 18 years - 66+
Gender: All
Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance
This is a partially blinded randomized controlled phase II pilot study comparing Poly-ICLC (Hiltonol®) treatment vs no treatment, for prostate cancer participants on active surveillance.
Age: 18 years - 66+
Gender: Male
Precision Medicine Study
This will be a 2 year study to evaluate and improve cancer sequencing as applied to the
characterization of tumor molecular make-up and the identification of novel therapeutics
(n=100). Participants who will undergo tumor biopsy for management of multiple myeloma
(MM...
Age: 18 years - 66+
Gender: All
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD)
in the following tumor types: endometrial cancer (EC); head and neck squamous cell
carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC);
hepatocel...
Age: 18 years - 66+
Gender: All
A Clinical Study of V940 Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Researchers are looking for new ways to treat people with high-risk muscle-invasive
urothelial carcinoma (MIUC). Urothelial carcinoma is a type of bladder cancer that begins
in cells that line the inside of the bladder and other parts of the urinary tract, such
as pa...
Age: 18 years - 66+
Gender: All
Tier - Palliative Care for Patients with Advanced Heart Failure or Cancer
TIER-PC is an adaptive model of delivering palliative care that provides the right level
of care to the right patients at the right time. It represents an adaption of the Mount
Sinai PALLIATIVE CARE AT HOME (PC@H) program, which delivers home-based palliative care.
T...
Age: 18 years - 66+
Gender: All